Intestinal type | Pancreatobiliary type | |||||
---|---|---|---|---|---|---|
Unadjusted | Adjusted | Unadjusted | Adjusted | |||
n(events) | HR(95%CI) | HR(95%CI) | n(events) | HR(95%CI) | HR(95%CI) | |
Age | ||||||
Continuous | 61 (30) | 1.02 (0.98–1.06) | 1.07 (1.02–1.13) | 106 (82) | 0.99 (0.96–1.02) | 1.01 (0.98–1.05) |
Gender | ||||||
Female | 34 (13) | 1.00 | 1.00 | 50 (36) | 1.00 | 1.00 |
Male | 27 (17) | 1.85 (0.89–3.84) | 2.12 (0.86–5.22) | 56 (46) | 1.20 (0.78–1.87) | 1.22 (0.76–1.95) |
Tumour origin | ||||||
Duodenum | 13 (5) | 1.00 | 1.00 | _ | _ | |
Ampulla-Intestinal type | 48 (25) | 1.49 (0.57–3.88) | 7.77 (1.86–32.39) | _ | _ | |
Ampulla-Pancreatobiliary type | _ | _ | 19 (16) | 1.00 | 1.00 | |
Distal Bile duct | _ | _ | 44 (32) | 0.74 (0.40–1.34) | 1.03 (0.50–2.15) | |
Pancreas | _ | _ | 43 (34) | 0.91 (0.50–1.65) | 1.06 (0.52–2.19) | |
Tumour size | ||||||
Continuous | 61 (30) | 1.00 (0.98–1.03) | 1.05 (1.01–1.10) | 106 (82) | 1.03 (1.01–1.05) | 1.01 (0.99–1.04) |
T-stage | ||||||
T1 | 4 (2) | 1.00 | 1.00 | 2 (1) | 1.00 | 1.00 |
T2 | 10(3) | 0.65 (0.11–3.88) | 0.55 (0.07–4.50) | 10 (6) | 1.43 (0.17–11.85) | 0.77 (0.08–7.56) |
T3 | 25 (9) | 0.94 (0.20–4.37) | 1.49 (0.19–11.34) | 77 (60) | 2.95 (0.41–21.34) | 0.84 (0.10–7.08) |
T4 | 22 (16) | 2.55 (0.58–11.15) | 1.88 (0.19–18.25) | 17 (15) | 3.77 (0.50–28.71) | 2.12 (0.09–48.78) |
N-stage | ||||||
N0 | 33 (15) | 1.00 | 1.00 | 29 (18) | 1.00 | 1.00 |
N1 (metastasis in 1–3 lgl) | 19 (9) | 1.17 (0.51–2.68) | 0.55 (0.20–1.50) | 45 (37) | 2.41 (1.35–4.29) | 2.85 (1.57–5.17) |
N2 (metastasis in 4 or more lgl) | 9 (6) | 2.08 (0.80–5.37) | 8.96 (2.47–32.51) | 32 (27) | 2.59 (1.40–4.78) | 2.45 (1.30–4.63) |
Differentiation grade | ||||||
Well-moderate | 30 (12) | 1.00 | 1.00 | 39 (24) | 1.00 | 1.00 |
Poor | 31 (18) | 1.98 (0.95–4.11) | 2.16 (0.77–6.03) | 67 (58) | 2.44 (1.50–3.95) | 2.13 (1.28–3.54) |
Involved margins, status | ||||||
R0 | 17 (4) | 1.00 | 1.00 | 6 (2) | 1.00 | 1.00 |
R1 & Rx | 44 (26) | 2.56 (0.89–7.36) | 0.46 (0.12–1.69) | 100 (80) | 3.49 (0.86–14.25) | 2.57 (0.62–10.60) |
Lymphatic growth | ||||||
Absent | 28 (7) | 1.00 | 1.00 | 32 (22) | 1.00 | 1.00 |
Present | 33 (23) | 3.61 (1.55–8.44) | 5.85 (1.93–17.77) | 74 (60) | 1.51 (0.92–2.48) | 0.96 (0.55–1.70) |
Vascular growth | ||||||
Absent | 56 (25) | 1.00 | 1.00 | 70 (47) | 1.00 | 1.00 |
Present | 5 (5) | 7.78 (2.74–22.11) | 1.70 (0.40–7.31) | 36 (35) | 2.39 (1.54–3.72) | 2.45 (1.54–3.87) |
Perineural growth | ||||||
Absent | 42 (17) | 1.00 | 1.00 | 22 (14) | 1.00 | 1.00 |
Present | 19 (13) | 2.15 (1.04–4.44) | 3.81 (1.55–9.37) | 84 (68) | 1.88 (1.05–3.38) | 0.92 (0.48–1.76) |
Growth in peripancreatic fat | ||||||
Absent | 40 (14) | 1.00 | 1.00 | 22 (14) | 1.00 | 1.00 |
Present | 21 (16) | 3.49 (1.68–7.25) | 0.75 (0.06–9.94) | 84 (68) | 1.80 (1.00–3.25) | 1.25 (0.64–2.43) |
Adjuvant treatment | ||||||
No | 43 (24) | 1.00 | 1.00 | 49 (39) | 1.00 | 1.00 |
Yes | 18 (6) | 0.60 (0.25–1.47) | 0.03 (0.01–0.16) | 57 (43) | 0.90 (0.58–1.39) | 0.67 (0.43–1.04) |
PODXL expression | ||||||
Non-membranous | 49 (21) | 1.00 | 1.00 | 51 (38) | 1.00 | 1.00 |
Membranous | 12 (9) | 2.32 (1.05–5.12) | 7.31 (2.12–25.16) | 55 (44) | 1.32 (0.85–2.03) | 1.10 (0.67–1.81) |